Gonadorelin (GnRH) (2 mg Vial) Dosage Protocol
Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH), a 10-amino-acid hypothalamic peptide that stimulates pituitary LH and FSH release.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and periodic dosing
Standard / Maintenance Approach (2 mL = 1 mg/mL)
Route: Subcutaneous injection. Frequency: 2–3 times per week on non‑consecutive days (e.g., Mon/Wed/Fri or Tue/Thu/Sat).
| Week/Phase | Dose per Injection (mcg) | Units (mL) |
|---|---|---|
| Weeks 1–2 (Initiation) | 50 mcg | 5 units (0.05 mL) |
| Weeks 3–4 (Titration) | 100 mcg | 10 units (0.10 mL) |
| Weeks 5–8 (Maintenance) | 100–150 mcg | 10–15 units (0.10–0.15 mL) |
For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label concentration (1 mg/mL) and date; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Advanced / Post‑Cycle Support Approach
Route: Subcutaneous injection. Frequency: Daily or every other day for short cycles (limit to ≤14 consecutive days to avoid pituitary desensitization).
| Week/Phase | Dose per Injection (mcg) | Units (mL) |
|---|---|---|
| Days 1–7 (Burst) | 200 mcg | 20 units (0.20 mL) |
| Days 8–14 (Taper) | 100 mcg | 10 units (0.10 mL) |
| Week 3+ (Optional Maintenance) | 100 mcg 2–3×/wk | 10 units (0.10 mL) |
Important: Limit consecutive daily dosing to ≤14 days. Extended continuous administration may lead to GnRH receptor desensitization and reduced LH/FSH response.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on a 4–8 week protocol with 2–3 injections per week.
| Item | Quantity |
|---|---|
| Peptide Vials (Gonadorelin, 2 mg each) | 4 weeks (100 mcg × 3/wk) ≈ 1 vial 6 weeks (100 mcg × 3/wk) ≈ 1 vial 8 weeks (150 mcg × 3/wk) ≈ 2 vials |
| Insulin Syringes (U‑100, 30‑ or 50‑unit preferred) | Per week: 3 syringes 4 weeks: 12 syringes 6 weeks: 18 syringes 8 weeks: 24 syringes |
| Bacteriostatic Water (10 mL bottles) | 4–6 weeks (1 vial): 2 mL → 1 × 10 mL bottle 8 weeks (2 vials): 4 mL → 1 × 10 mL bottle |
| Alcohol Swabs | Per week: 6 swabs (2/injection × 3 injections) 4 weeks: 24 swabs 6 weeks: 36 swabs 8 weeks: 48 swabs → recommend 1 × 100‑count box |
Protocol Overview
Gonadorelin (synthetic GnRH) stimulates the entire HPG axis upstream of HCG — preserving pituitary function rather than just testicular Leydig cells.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days, protect from light |
Important Notes
How This Works
Gonadorelin is the active form of native GnRH, a 10-amino-acid hypothalamic decapeptide that stimulates the anterior pituitary to release LH and FSH. The pituitary GnRH receptor requires pulsatile stimulation — continuous high-dose exposure produces receptor desensitization, which is the basis for GnRH agonist use as androgen deprivation in prostate cancer.
For testicular function maintenance during TRT (alternative to HCG), gonadorelin is dosed in pulsatile patterns mimicking natural hypothalamic release, preserving the pituitary-gonadal axis upstream of LH/FSH.
Potential Benefits & Side Effects
Potential Benefits
- Preserves entire HPG axis (vs HCG which acts only at the gonadal level).
- Useful as TRT adjunct for axis preservation.
- Used in fertility restoration protocols.
Side Effect Profile
- Injection-site reactions.
- Continuous (non-pulsatile) high-dose use causes desensitization.
- Mild headache or flushing post-dose.
Lifestyle Factors
- Pulsatile dosing (every 90 min) is more physiological but impractical without pump.
- Most research-grade protocols use 2–3× weekly bolus dosing.
- Pair with bloodwork (LH, FSH, T) every 8–12 weeks.
Injection Technique
- Subcutaneous, rotate sites.
- 90° angle with short insulin needle.